Statin-Associated Muscle Adverse Events : Update for clinicians
Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common,...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sultan Qaboos University
2016-11-01
|
| Series: | Sultan Qaboos University Medical Journal |
| Subjects: | |
| Online Access: | https://journals.squ.edu.om/index.php/squmj/article/view/2178 |
| _version_ | 1818276093067526144 |
|---|---|
| author | Maha A. Al-Mohaissen Martha J. Ignaszewski Jiri Frohlich Andrew P. Ignaszewski |
| author_facet | Maha A. Al-Mohaissen Martha J. Ignaszewski Jiri Frohlich Andrew P. Ignaszewski |
| author_sort | Maha A. Al-Mohaissen |
| collection | DOAJ |
| description | Statins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies. |
| first_indexed | 2024-12-12T22:40:10Z |
| format | Article |
| id | doaj.art-c745aa63705a4498b3d21b3778271b53 |
| institution | Directory Open Access Journal |
| issn | 2075-051X 2075-0528 |
| language | English |
| last_indexed | 2024-12-12T22:40:10Z |
| publishDate | 2016-11-01 |
| publisher | Sultan Qaboos University |
| record_format | Article |
| series | Sultan Qaboos University Medical Journal |
| spelling | doaj.art-c745aa63705a4498b3d21b3778271b532022-12-22T00:09:22ZengSultan Qaboos UniversitySultan Qaboos University Medical Journal2075-051X2075-05282016-11-0116440641510.18295/squmj.2016.16.04.0022098Statin-Associated Muscle Adverse Events : Update for cliniciansMaha A. Al-Mohaissen0Martha J. Ignaszewski1Jiri Frohlich2Andrew P. Ignaszewski3Department of Clinical Sciences, College of Medicine, Princess Nourah bint Abdulrahman University, Riyadh, Saudi ArabiaDepartment of Psychiatry, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts, USADepartments of Pathology & Laboratory Medicine Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaDepartments of Cardiology, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaStatins are potent medications which reduce low-density lipoprotein cholesterol (LDL-C) levels. Their efficacy in cardiovascular risk reduction is well established and indications for their use are expanding. While statins are generally well tolerated and safe, adverse events are relatively common, particularly statinassociated muscle adverse events (SaMAEs), which are the most frequently encountered type of adverse event. Recent guidelines and guideline updates on SaMAEs and statin intolerance have included revised definitions of SaMAEs, incorporating new evidence on their pathogenesis and management. As SaMAEs emerge as a therapeutic challenge, it is important for physicians to be aware of updates on management strategies to ensure better patient outcomes. The majority of patients who are considered statin-intolerant can nevertheless tolerate some forms of statin therapy and successfully achieve optimal LDL-C levels. This review article discusses the recent classification of SaMAEs with emphasis on pathogenesis and management strategies.https://journals.squ.edu.om/index.php/squmj/article/view/2178hydroxymethylglutaryl-coa reductase inhibitorshyperlipidemiashypercholesterolemiamyopathiesadverse effects. |
| spellingShingle | Maha A. Al-Mohaissen Martha J. Ignaszewski Jiri Frohlich Andrew P. Ignaszewski Statin-Associated Muscle Adverse Events : Update for clinicians Sultan Qaboos University Medical Journal hydroxymethylglutaryl-coa reductase inhibitors hyperlipidemias hypercholesterolemia myopathies adverse effects. |
| title | Statin-Associated Muscle Adverse Events : Update for clinicians |
| title_full | Statin-Associated Muscle Adverse Events : Update for clinicians |
| title_fullStr | Statin-Associated Muscle Adverse Events : Update for clinicians |
| title_full_unstemmed | Statin-Associated Muscle Adverse Events : Update for clinicians |
| title_short | Statin-Associated Muscle Adverse Events : Update for clinicians |
| title_sort | statin associated muscle adverse events update for clinicians |
| topic | hydroxymethylglutaryl-coa reductase inhibitors hyperlipidemias hypercholesterolemia myopathies adverse effects. |
| url | https://journals.squ.edu.om/index.php/squmj/article/view/2178 |
| work_keys_str_mv | AT mahaaalmohaissen statinassociatedmuscleadverseeventsupdateforclinicians AT marthajignaszewski statinassociatedmuscleadverseeventsupdateforclinicians AT jirifrohlich statinassociatedmuscleadverseeventsupdateforclinicians AT andrewpignaszewski statinassociatedmuscleadverseeventsupdateforclinicians |